Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome
This study has been completed.
Sponsor:
Yonsei University
Information provided by (Responsible Party):
Yonsei University
ClinicalTrials.gov Identifier:
NCT01384656
First received: June 27, 2011
Last updated: March 4, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients undergoing multivessel off-pump coronary bypass surgery (OPCAB) inevitably experience cumulative ischemia-reperfusion injury at myocardium. Glucose-insulin-potassium (GIK) is a potentially useful adjunct to myocardial protection. This study was designed to evaluate the effects of GIK infusion on myocardium in patients undergoing OPCAB. Patients undergoing OPCAB with acute coronary syndrome are randomly assigned to GIK or Control group. The trial is double-blind and conducted at a single center.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Coronary Syndrome |
Drug: GIK solution |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome |
Resource links provided by NLM:
Further study details as provided by Yonsei University:
Primary Outcome Measures:
- CK-MB(creatinine kinase-MB) mass [ Time Frame: 12 hours after the surgery ] [ Designated as safety issue: No ]Comparison of cardiac enzyme elevation after surgery between GIK and Control group.
| Enrollment: | 66 |
| Study Start Date: | February 2011 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: GIK group |
Drug: GIK solution
Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Other Name: glucose-insulin-potassium(GIK) solution
|
| Placebo Comparator: Control group |
Drug: GIK solution
Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Other Name: glucose-insulin-potassium(GIK) solution
|
Eligibility| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients undergoing isolated OPCAB.
- Age: 20~75.
Exclusion Criteria:
- Emergency operation.
- Patients with MR ≥ 2.
- Patients with IDDM.
- Patients with random sugar ≥ 250 mg/dL.
- Patients with serum creatinine ≥ 2.0 mg/dL.
- Patients with acute myocardial infarction within 1 week of surgery
Contacts and Locations
More Information
No publications provided by Yonsei University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Yonsei University |
| ClinicalTrials.gov Identifier: | NCT01384656 History of Changes |
| Other Study ID Numbers: | 4-2009-0689 |
| Study First Received: | June 27, 2011 |
| Last Updated: | March 4, 2013 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Additional relevant MeSH terms:
|
Acute Coronary Syndrome Myocardial Ischemia Heart Diseases Cardiovascular Diseases Angina Pectoris Vascular Diseases Chest Pain |
Pain Signs and Symptoms Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013